Archives
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
October 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
December 2003
November 2003
October 2003
September 2003
August 2003
July 2003
June 2003
May 2003
April 2003
March 2003
February 2003
January 2003
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
December 2001
November 2001
October 2001
September 2001
August 2001
July 2001
June 2001
May 2001
April 2001
March 2001
February 2001
January 2001
December 2000
November 2000
October 2000
September 2000
August 2000
July 2000
June 2000
May 2000
April 2000
March 2000
February 2000
January 2000
December 1999
November 1999
October 1999
September 1999
August 1999
June 1999
May 1999
April 1999
April 1998
|
Developing states attack EU on generic drug seizure
Reuters
February 26, 2009
By Jonathan Lynn
GENEVA - Developing countries accused the European Union on Monday of seeking to use tough intellectual property laws to seize generic drugs, putting lives at risk in emerging nations where the cheaper medicines are often destined. At a meeting of the World Trade Organisation, Brazil and India criticised the European Union over an Indian generic drug to treat high blood pressure that was in seized late last year while transit in the Netherlands for Brazil. Like many developing countries, Brazil argues that it can withhold intellectual property rights for a drug if there is an overriding public interest. High blood pressure is a leading cause of death in the South American country. Brazil's WTO ambassador Roberto Azevedo told the WTO's General Council the case reflected a trend by industrialised countries to try and circumvent global trade rules by pushing tough intellectual property standards in other bodies, such as the World Customs Organisation and World Health Organisation. The case touches on one of the most sensitive issues between rich and poor countries -- access to affordable medicine -- and has been cited by developing countries as an example of rising protectionism in the economic crisis. "The decision to impede the transit of a cargo of generic medicines -- which was not headed for the Dutch market -- is unacceptable and sets a dangerous precedent," Brazil's WTO ambassador, Roberto Azevedo, told the WTO's General Council. "Worse still, there are indications that this is not an isolated case," he said, according to a text of his remarks. DRUGS SENT BACK EU ambassador Eckart Guth criticised the "highly emotional debate" and warned fellow WTO members against jumping to wrong conclusions or blowing the case out of proportion. "Let me make it very clear that the EU has absolutely no intention to hamper any legitimate trade in generic medicines or to create legal barriers to prevent movement of drugs to developing countries," he told the WTO council. Azevedo argued trade in generic medicines was completely legal under WTO rules and won backing from India and speakers from 17 other developing countries, including South Africa, Indonesia, China, Pakistan and Israel. Dutch authorities seized the consignment of 500 kilos of a generic version of the arterial hypertension drug losartan at the request of a company holding Dutch patent rights on Dec. 4. The drug is not patent-protected in Brazil or India. Guth said the shipment, worth 55,000 euros ($70,730) was detained under WTO rules allowing customs to temporarily hold goods suspected of infringing intellectual property rights. After 36 days they were returned to the Indian owner, and flown back to India, never reaching Brazil. The generic version of the drug is manufactured in India by Dr. Reddy's Laboratories. Losartan is the generic name for the drug Cozaar developed jointly by Merck & Co and Dupont Co. Trade sources said Merck is the patent holder in the Netherlands under the name Merck Sharp & Dohme. The WTO General Council also approved a new chairman for the year, Chilean ambassador Mario Matus, 52. Matus previous chaired the WTO's dispute settlement body, which handles trade disputes worth billions of dollars. Matus was replaced as dispute settlement body chairman -- a position which often leads to the council chairmanship -- by Canadian ambassador John Gero.
NOTICE: In
accordance with Title 17 U.S.C. Section 107, this material is
distributed without profit to those who have expressed a prior
interest in receiving this information for research and
educational purposes.
|